Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Sangamo Therapeutics (SGMO) Receivables - Other (2016 - 2024)

Sangamo Therapeutics has reported Receivables - Other over the past 15 years, most recently at $4.1 million for Q4 2024.

  • Quarterly results put Receivables - Other at $4.1 million for Q4 2024, up 917.37% from a year ago — trailing twelve months through Dec 2024 was $4.1 million (up 917.37% YoY), and the annual figure for FY2024 was $4.1 million, up 917.37%.
  • Receivables - Other for Q4 2024 was $4.1 million at Sangamo Therapeutics, down from $10.0 million in the prior quarter.
  • Over the last five years, Receivables - Other for SGMO hit a ceiling of $10.0 million in Q3 2024 and a floor of $349000.0 in Q4 2021.
  • Median Receivables - Other over the past 5 years was $874000.0 (2020), compared with a mean of $2.2 million.
  • Biggest five-year swings in Receivables - Other: plummeted 66.28% in 2021 and later skyrocketed 1561.13% in 2024.
  • Sangamo Therapeutics' Receivables - Other stood at $1.0 million in 2020, then tumbled by 66.28% to $349000.0 in 2021, then surged by 127.51% to $794000.0 in 2022, then crashed by 49.24% to $403000.0 in 2023, then surged by 917.37% to $4.1 million in 2024.
  • The last three reported values for Receivables - Other were $4.1 million (Q4 2024), $10.0 million (Q3 2024), and $403000.0 (Q4 2023) per Business Quant data.